At the booth of Gilead Sciences, Lenacapavir, to be used as the world's only twice-yearly, long-acting injectable for HIV ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Regulatory mechanisms governing stem cell quiescence in glandular organs remain ill-defined. Here, multi-omics profiling ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

Discover key Q3 2025 earnings insights for Illumina, including raised outlook, NovaSeq X growth, and margin expansion.

Illumina (($ILMN)) has held its Q3 earnings call. Read on for the main highlights of the call. Illumina’s recent earnings call painted a picture ...

According to Nova One Advisor, the global genomics data analysis market size is calculated at USD 7.91 billion in 2025 and is ...

Sequencing treatment for patients with relapsed or refractory multiple myeloma depends on the patient’s disease and history, explained Lisa Hwa Christenson, DNP, APRN, CNP, associate professor of ...